AU2001280908A1 - Rotavirus vaccine formulations - Google Patents

Rotavirus vaccine formulations

Info

Publication number
AU2001280908A1
AU2001280908A1 AU2001280908A AU8090801A AU2001280908A1 AU 2001280908 A1 AU2001280908 A1 AU 2001280908A1 AU 2001280908 A AU2001280908 A AU 2001280908A AU 8090801 A AU8090801 A AU 8090801A AU 2001280908 A1 AU2001280908 A1 AU 2001280908A1
Authority
AU
Australia
Prior art keywords
vaccine formulations
rotavirus vaccine
rotavirus
formulations
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280908A
Inventor
Carl J. Burke
David B. Volkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2001280908A1 publication Critical patent/AU2001280908A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2001280908A 2000-08-03 2001-07-20 Rotavirus vaccine formulations Abandoned AU2001280908A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09631807 2000-08-03
US09/631,807 US6616931B1 (en) 1996-09-26 2000-08-03 Rotavirus vaccine formulations
PCT/US2001/023926 WO2002011540A1 (en) 2000-08-03 2001-07-20 Rotavirus vaccine formulations

Publications (1)

Publication Number Publication Date
AU2001280908A1 true AU2001280908A1 (en) 2002-02-18

Family

ID=24532815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280908A Abandoned AU2001280908A1 (en) 2000-08-03 2001-07-20 Rotavirus vaccine formulations

Country Status (3)

Country Link
US (1) US6616931B1 (en)
AU (1) AU2001280908A1 (en)
WO (1) WO2002011540A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CA2630349A1 (en) * 2005-11-21 2007-05-24 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
AU2007251122B2 (en) * 2006-05-12 2013-01-10 Bharat Biotech International Limited A composition useful as a vaccine
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
KR101562971B1 (en) 2007-04-06 2015-10-23 다케다 백신즈 인코포레이티드 Methods and compositions for live attenuated viruses
US8241886B2 (en) * 2007-09-25 2012-08-14 Aridis Pharmaceuticals Formulations for preservation of rotavirus
CN102695522B (en) 2009-05-12 2016-10-19 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) New Human reoviruslike agent strain and vaccine
CN102470170B (en) * 2009-07-13 2015-03-18 巴拉特生物技术国际有限公司 Composition useful as rotavirus vaccine and a method therefor
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
ES2630012T3 (en) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Freeze-dried viral formulations
WO2012103464A2 (en) * 2011-01-28 2012-08-02 Brian Pulliam Oral thin film vaccine preparation
KR20150000389A (en) * 2011-04-28 2015-01-02 인터내셔널 메디카 파운데이션 Liquid vaccine preparations
EP2747777A4 (en) * 2011-08-25 2015-04-29 Brian Pulliam Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures
JP6126684B2 (en) 2012-04-23 2017-05-10 バハラ バイオテック インターナショナル リミテッド Novel rotavirus vaccine composition and method for preparing the same
JP6674944B2 (en) * 2014-07-18 2020-04-01 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. Improved thermostable spray-dried rotavirus vaccine formulation and method for producing the same
BR112017000515A2 (en) * 2014-07-18 2017-11-14 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd lyophilization-dried thermostable rotavirus vaccine formulation and process for preparing it
RU2018126322A (en) * 2015-12-18 2020-01-20 Мерк Шарп И Доум Корп. THERMALLY STABLE ROTAVIRAL VACCINE COMPOSITIONS AND WAYS OF THEIR APPLICATION
GB201602880D0 (en) 2016-02-18 2016-04-06 Ge Healthcare Uk Ltd Method and composition for biomolecule stabilization
MA44557B1 (en) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd BUFFER-FREE, ACID-STABLE, LOW-DOSAGE ROTAVIRUS VACCINE
TWI641725B (en) * 2016-11-15 2018-11-21 添鴻科技股份有限公司 Etching solution for titanium-tungsten alloy
MX2019008105A (en) 2017-01-06 2020-07-22 Stabilitech Biopharma Ltd Virus.
US10413604B2 (en) 2017-02-14 2019-09-17 Inventprise, Llc Heat stable liquid rotavirus vaccine
US11110163B2 (en) 2017-02-14 2021-09-07 Inventprise, Llc Heat stable vaccines
CN107174663B (en) * 2017-05-22 2020-06-30 杭州洪晟生物技术股份有限公司 Vaccine freeze-drying protective agent
CN108624505A (en) * 2018-08-29 2018-10-09 上海比昂生物医药科技有限公司 A kind of slow virus freezing drying protective agent and slow virus freeze-dried powder
CN114392237B (en) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 Freeze-dried virus preparation and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations

Also Published As

Publication number Publication date
WO2002011540A1 (en) 2002-02-14
US6616931B1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
AU2001280908A1 (en) Rotavirus vaccine formulations
AU2001279972A1 (en) Pesticidal formulations
GB0020953D0 (en) Vaccine
HUP0301043A3 (en) Vaccine
IL155072A0 (en) Vaccine
HUP0301413A3 (en) Vaccine compositions
AU2001258279A1 (en) Adjuvant for vaccines
AU1591402A (en) Vaccine
AU2001267707A1 (en) Antiperspirant formulations
GB0015490D0 (en) Novel formulations
GB0014288D0 (en) Vaccine
AU2002210407A1 (en) Therapeutic vaccine formulations containing chitosan
AU2001267693A1 (en) Antiperspirant formulations
AU6158700A (en) Vaccine
AU2001267541A1 (en) Vaccine composition
GB0026334D0 (en) Vaccine
GB0014845D0 (en) Vaccine
GB0025694D0 (en) Vaccine
AU5811600A (en) Vaccine
AU1101701A (en) Vaccine compositions
GB0003082D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
AU2001266534A1 (en) Papillomavirus vaccine
AU3397101A (en) Adjuvants
GB0006693D0 (en) Vaccine